T1	Person 0 4	Male
T2	Person 7 13	female
T3	Value 23 43	>= 18 and < 70 years
T4	Person 47 50	age
*	OR T2 T1
R1	Has_value Arg1:T4 Arg2:T3	
T5	Measurement 61 66	HBeAg
T6	Value 52 60	Positive
R2	Has_value Arg1:T5 Arg2:T6	
T7	Temporal 67 95	before starting NA treatment
T8	Reference_point 74 95	starting NA treatment
R3	Has_index Arg1:T7 Arg2:T8	
R4	Has_temporal Arg1:T5 Arg2:T7	
T9	Drug 121 131	lamivudine
T10	Drug 133 141	adefovir
T11	Drug 143 152	entecavir
T12	Drug 156 165	tenofovir
*	OR T12 T11 T10 T9
T13	Multiplier 110 116	single
T14	Drug 117 119	NA
R5	Has_multiplier Arg1:T14 Arg2:T13	
T15	Procedure 97 104	Treated
R6	AND Arg1:T15 Arg2:T14	
T16	Scope 121 165	lamivudine, adefovir, entecavir or tenofovir
R7	Subsumes Arg1:T14 Arg2:T16	
T17	Temporal 167 190	for 6 months to 5 years
R8	Has_temporal Arg1:T15 Arg2:T17	
T18	Measurement 202 207	HBeAg
T19	Value 208 222	seroconversion
T20	Measurement 224 229	HBeAg
T21	Measurement 243 250	ant-HBe
T22	Value 230 238	negative
T23	Value 251 259	negative
*	OR T21 T23
*	OR T20 T22
*	OR T18 T19
T24	Scope 224 259	HBeAg negative and ant-HBe negative
R9	Subsumes Arg1:T19 Arg2:T24	
T25	Value 266 278	undetectable
T26	Measurement 279 286	HBV DNA
T27	Procedure 290 305	PCR based assay
T28	Drug 309 311	NA
T29	Procedure 312 321	treatment
R10	AND Arg1:T29 Arg2:T28	
R11	Has_value Arg1:T26 Arg2:T25	
R12	AND Arg1:T27 Arg2:T26	
R13	AND Arg1:T27 Arg2:T29	
T30	Value 324 332	Negative
T31	Measurement 342 362	serum pregnancy test
T32	Measurement 333 338;348 362	urine pregnancy test
*	OR T31 T32
T33	Scope 333 362	urine or serum pregnancy test
R14	Has_value Arg1:T33 Arg2:T30	
T34	Person 368 373	women
T35	Condition 377 399	childbearing potential
T36	Scope 368 399	women of childbearing potential
A1	Optional T36
R15	Has_scope Arg1:T36 Arg2:T33	
T37	Temporal 412 474	within the 24-hour period prior to the first dose of test drug
T38	Reference_point 447 474	the first dose of test drug
R16	Has_index Arg1:T37 Arg2:T38	
R17	Has_temporal Arg1:T33 Arg2:T37	
T39	Pregnancy_considerations 476 599	Additionally, all females must be using reliable contraception during the study and for 3 months after treatment completion
